Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.

Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...

The U.S. Food and Drug Administration (FDA) has approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have specific HER2 ...

Lung cancer is now the leading cause of cancer deaths in the United States, claiming more lives than several other major ...

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.

Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

Researchers from Ohio State University, led by Distinguished Professor John J. Coccyx and graduate student Arshad Ahmad from Heritage College of Osteopathic Medicine have discovered a potential new ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

Suchan still needed chemotherapy and radiation, but Salgia credits Rybrevant for shrinking her tumors 60 to 70%. It specifically targets her cancer cells and revs up the immune system. For a year and ...

This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...